Dermata Therapeutics (DRMA) Long-Term Debt Issuances (2020 - 2021)
Dermata Therapeutics (DRMA) posted quarterly Long-Term Debt Issuances of $1.6 million for Q1 2021, up 136.58% quarter-over-quarter from $660550.0 in Q4 2020.
Dermata Therapeutics (DRMA) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends
Dermata Therapeutics' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $1.6 million for Q1 2021.
- In Q1 2021, Long-Term Debt Issuances changed N/A year-over-year to $1.6 million; the TTM figure through Dec 2021 stood at $1.6 million (changed N/A YoY), while the FY2021 annual figure was $1.6 million, down 47.47% from the prior year.
- Long-Term Debt Issuances for Q1 2021 stood at $1.6 million, up from $660550.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $1.7 million in Q3 2020, with the low at $660550.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 1.56 Mn |
| Mar 31, 2021 | 1.56 Mn |
| Dec 31, 2020 | 660,550.00 |
| Dec 31, 2020 | 660,550.00 |
| Sep 30, 2020 | 1.71 Mn |
| Sep 30, 2020 | 1.71 Mn |